淮海医药
淮海醫藥
회해의약
JOURNAL OF HUAIHAI MEDICINE
2014年
5期
417-418
,共2页
陈松林%梁茵颖%朱荣兰%姚璐%刘小云%张常然%郑慧玲
陳鬆林%樑茵穎%硃榮蘭%姚璐%劉小雲%張常然%鄭慧玲
진송림%량인영%주영란%요로%류소운%장상연%정혜령
红斑肢痛症%营养神经%改善循环%治疗
紅斑肢痛癥%營養神經%改善循環%治療
홍반지통증%영양신경%개선순배%치료
Erythromelalgia%Nourishing nerve%Improving circulation%Treatment
目的:评价改善循环、营养神经方法治疗红斑肢痛症的疗效和安全性。方法7例临床诊断的红斑肢痛症患者给予营养神经:水溶性维生素1支(0.486 g/支),iv drip,qd,奥德金1.2 g,iv drip,qd;改善循环:参麦60 ml iv drip, qd,的方法治疗,约3周后,观察其疗效和安全性。结果7例红斑肢痛症的患者,经过约3周的治疗,其临床症状消失;治疗前后检查血尿常规,肝肾功能,心电图,未见异常。跟踪观察3月,1例患者症状复发,但症状较治疗前减轻。重复治疗2周,患者症状完全缓解,跟踪观察3月,患者症状未再复发。结论改善循环、营养神经方法治疗红斑肢痛症安全有效。
目的:評價改善循環、營養神經方法治療紅斑肢痛癥的療效和安全性。方法7例臨床診斷的紅斑肢痛癥患者給予營養神經:水溶性維生素1支(0.486 g/支),iv drip,qd,奧德金1.2 g,iv drip,qd;改善循環:參麥60 ml iv drip, qd,的方法治療,約3週後,觀察其療效和安全性。結果7例紅斑肢痛癥的患者,經過約3週的治療,其臨床癥狀消失;治療前後檢查血尿常規,肝腎功能,心電圖,未見異常。跟蹤觀察3月,1例患者癥狀複髮,但癥狀較治療前減輕。重複治療2週,患者癥狀完全緩解,跟蹤觀察3月,患者癥狀未再複髮。結論改善循環、營養神經方法治療紅斑肢痛癥安全有效。
목적:평개개선순배、영양신경방법치료홍반지통증적료효화안전성。방법7례림상진단적홍반지통증환자급여영양신경:수용성유생소1지(0.486 g/지),iv drip,qd,오덕금1.2 g,iv drip,qd;개선순배:삼맥60 ml iv drip, qd,적방법치료,약3주후,관찰기료효화안전성。결과7례홍반지통증적환자,경과약3주적치료,기림상증상소실;치료전후검사혈뇨상규,간신공능,심전도,미견이상。근종관찰3월,1례환자증상복발,단증상교치료전감경。중복치료2주,환자증상완전완해,근종관찰3월,환자증상미재복발。결론개선순배、영양신경방법치료홍반지통증안전유효。
Objective To investigate the efficacy and safety for primary erythromelalgia ( PE) treatment with therapy of improving blood circulation and nourishing peripheral nerves .Methods 7 patients were given intravenous injection of shen-mai,water-soluble vitamins,and deproteinised calf blood per day for 3 weeks and efficacy and safety were observed and evalua-ted.Results After the treating cycle , the symptoms of the 7 patients disappeared completely .Before and after the treatment , no abnormal changes were observed in terms of their blood and urine routines ,the function of liver and kidney and ECG .After 3 months'follow-up,1 case had a relapse .But after a repeated treatment of 2 weeks with the original therapy ,the symptoms dis-appeared totally .After another 3 months'follow-up,the symptoms did not recur .Conclusion The therapy of improving blood circulation and nourishing nerves is safe and effective for the treatment of PE .